The National Cancer Institute (NCI) awarded a $396,161 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Olmeda Biosciences LLC, a self-certified small disadvantaged business in San Diego, CA. The grant funding supports the development of a novel aqueous humor-based multiplex assay for predicting the metastatic risk of uveal melanoma, a prevalent intraocular cancer affecting an estimated 60,000-70,000 individuals in the U.S. The innovative approach seeks to create a less invasive prognostic tool compared to current methods, which rely on gene expression profiling from invasive needle biopsies. The project aims to leverage proteomic analysis of aqueous humor, the clear fluid from the eye's front chamber, to identify biomarkers that can accurately predict metastatic risk and guide treatment decisions. The research and development effort is expected to be completed by August 31, 2025.
Generated 3/4/25, 7:43 AM